Jake Goldstein

Jake Goldstein

Auto-generated profile, based on publicly available information

Jake Goldstein

Internal Medicine, University of Utah Health, Salt Lake City, Utah, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2023 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
VSVince Siebert
Vince Siebert
JGJake Goldstein
Jake Goldstein
RKRizwan Khan
Rizwan Khan
JLJohn Lopez
John Lopez
ADAmir Darki
Amir Darki
DDDemetrios Doukas
Demetrios Doukas
Background: Acute myocardial infarction complicated by cardiogenic shock (AMI‐CS) is the most common cause of mortality following AMI, and treatment algorithms vary widely. We report the results of an analysis using time‐sensitive, hemodynamic goals in the treatment of AMI‐CS in a single center study.Methods: Consecutive patients with AMI‐CS from November 2016 through December 2021 were included in our retrospective analysis. Clinical characteristics and outcomes were analyzed using the electronic medical records. We identified 63 total patients who were admitted to our center with AMI‐CS, and we excluded patients who did not have clear timing of AMI onset or CS onset. We evaluated the rate of survival to hospital discharge based on the quantity of certain time‐sensitive hemodynamic goals were met.Results: We identified 63 patients who met criteria for AMI‐CS, 39 (62%) of whom survived to hospital discharge. Odds of survival were closely related to the achievement of four time‐dependent goals: cardiac power output (CPO) >0.6 Watts (W), pulmonary artery pulsatility index (PAPi) >1, lactate <4 mmol/L, and 0.6 W, PAPi >1, <2 vasopressors, and lactate <4 mmol/L) at 24 h after treatment for AMI‐CS with in‐hospital mortality. Our data show, in line with previous data, that the higher number of goals met at 24 h was associated with improved in‐hospital mortality regardless of treatment strategy.

12 January 2022 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
PDF file
JGJake Goldstein
Jake Goldstein
RDRobert S Dieter
Robert S Dieter
VBVinod Bansal
Vinod Bansal
KWKeaton Wieschhaus
Keaton Wieschhaus
EBEmily Bontekoe
Emily Bontekoe
JFJawed Fareed
Jawed Fareed
Background: Patients with end-stage renal disease (ESRD) often present with an increased risk of cardiovascular disease. Conditions of compromised cardiovascular health such as atrial fibrillation (AFIB) and peripheral arterial disease (PAD) may alter biomarker levels in a way that reflects worsening ESRD. This study profiled biomarkers and laboratory parameters of endothelium dysfunction in patients with ESRD, categorized by additional AFIB and PAD conditions. Methods: Citrated blood samples were collected from 95 patients with ESRD. Biomarker levels were measured from plasma samples using sandwich ELISAs, including tissue plasminogen activator (tPA), D-dimer, and nitrotyrosine. Lab parameters, including BUN, calcium, creatinine, parathyroid hormone, phosphate, alkaline phosphatase, ferritin, transferrin, and total iron capacity, and patient comorbidities were obtained from patient medical records. The comorbidities were determined through provider notes, and evidence of applicable testing. Results: 14.89% of patients were found to have atrial fibrillation (n = 14), 30.85% of patients were found to have peripheral arterial disease (n = 29), and 6.38% of patients were found to have both peripheral arterial disease and atrial fibrillation (n = 6). When compared to patients with only ESRD, patients with ESRD and PAD showed elevated levels of D-Dimer (p = .0314) and nitrotyrosine (p = .0330). When compared to patients with only ESRD, patients with atrial fibrillation showed elevated levels of D-Dimer (p = .0372), nitrotyrosine (p = .0322), and tPA (p = .0198). Conclusion: When compared to patients with just ESRD, patients with concomitant PAD had elevated levels of Nitrotyrosine and D-dimer; while patients with concomitant Afib had elevated levels of nitrotyrosine, D-dimer, as well as tPA.

2 July 2026 in Journal of Cardiac Failure - Intersections
Verified
Journal Article
Open access
JBJackson S. Burton
Jackson S. Burton
FRForest Riekhof
Forest Riekhof
JGJake Goldstein
Jake Goldstein
IKIoannis Kyriakoulis
Ioannis Kyriakoulis
EDElizabeth Dranow
Elizabeth Dranow
THThomas C. Hanff
Thomas C. Hanff

25 March 2025 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Open access
JJJoshua A. Jacobs
Joshua A. Jacobs
NHNicholas S. Hendren
Nicholas S. Hendren
KAKristin S. Alvarez
Kristin S. Alvarez
LSLeah J. Stinson
Leah J. Stinson
CMChris Mathew
Chris Mathew
SCSpencer J. Carter
Spencer J. Carter
Introduction: Oral metolazone and intravenous (IV) chlorothiazide have comparable diuretic efficacy and safety, although IV chlorothiazide is significantly more expensive. The use of electronic health record (EHR)‐based choice architecture interventions on the efficient use of diuretics remains unexplored.Objectives: We aimed to evaluate the impact of an EHR‐based choice architecture intervention on efficient chlorothiazide utilization at two United States institutions and highlight potential annual cost savings.Methods: Institution 1 implemented an educational intervention on August 1, 2020, followed by an EHR‐based intervention on January 1, 2021. Institution 2 implemented the EHR intervention alone on March 8, 2023. The EHR intervention prompted clinicians to consider switching to oral metolazone, emphasizing cost differences and similar efficacy. We compared mean weekly administrations and estimated rate ratios (RRs) and 95% confidence intervals (CIs) for the use of IV chlorothiazide for pre‐ versus post‐EHR intervention using interrupted time series analyses at each institution.Results: At Institution 1, mean weekly IV chlorothiazide administrations decreased from 42.3 ± 21.9 at baseline to 16.4 ± 13.7 post‐EHR intervention (p < 0.001), with an estimated annual cost savings of $175 000. At Institution 2, mean weekly administrations decreased from 20.3 ± 21.9 to 10.7 ± 5.7 (p = 0.04), with an estimated annual cost savings of $65 000. Interrupted time series analyses showed a significant reduction in IV chlorothiazide use associated with the EHR intervention (Institution 1: RR 0.56; 95% CI 0.33, 0.91; Institution 2: RR 0.45; 95% CI 0.31, 0.65).Conclusion: The EHR‐based interventions demonstrated significant reductions in IV chlorothiazide use and potentially substantial cost savings at two separate institutions, highlighting their potential as a scalable strategy to improve efficient diuretic utilization.

25 July 2025 in BMJ Case Reports
Verified
Journal Article
Closed access
JGJake Goldstein
Jake Goldstein
LSLeah Stinson
Leah Stinson
KSKonstantinos Sideris
Konstantinos Sideris
JWJill Waldron
Jill Waldron
RMRyan Mooney
Ryan Mooney
SCSpencer Carter
Spencer Carter
Transthyretin amyloidosis (ATTR) is an underdiagnosed multisystem disease. More than 140 known mutations are pathologic, and organ tropism can vary significantly based on the causative mutation. An elderly man with neuropathy and congestive heart failure was found to have left ventricular hypertrophy on echocardiogram. Subsequent endomyocardial biopsy demonstrated transthyretin amyloid deposition. On referral to our centre, genetic testing was performed, demonstrating a missense mutation, c.229G>A, that results in the amino acid substitution p.Gly77Arg. This mutation had only been reported in one other case of amyloidosis internationally. Cascade genetic testing ensued, which resulted in multiple family members having the same mutation with varying stages of disease activity. This case highlights the importance of genetic testing for all individuals diagnosed with ATTR regardless of age and the variable organ tropism of the disease.

11 October 2026 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
EMEleni Maneta
Eleni Maneta
IKIoannis Kyriakoulis
Ioannis Kyriakoulis
Christos P. KyriakopoulosChristos P. Kyriakopoulos
Christos P. Kyriakopoulos
BHBenjamin D. Horne
Benjamin D. Horne
EDElizabeth Dranow
Elizabeth Dranow
SDStavros G. Drakos
Stavros G. Drakos